BRPI0808503B8 - composto, uso de um composto, e, composição farmacêutica - Google Patents

composto, uso de um composto, e, composição farmacêutica

Info

Publication number
BRPI0808503B8
BRPI0808503B8 BRPI0808503A BRPI0808503A BRPI0808503B8 BR PI0808503 B8 BRPI0808503 B8 BR PI0808503B8 BR PI0808503 A BRPI0808503 A BR PI0808503A BR PI0808503 A BRPI0808503 A BR PI0808503A BR PI0808503 B8 BRPI0808503 B8 BR PI0808503B8
Authority
BR
Brazil
Prior art keywords
compound
relates
alzheimer
disease
compositions
Prior art date
Application number
BRPI0808503A
Other languages
English (en)
Inventor
Swahn Britt-Marie
Wensbo David
Arzel Erwan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0808503A2 publication Critical patent/BRPI0808503A2/pt
Publication of BRPI0808503B1 publication Critical patent/BRPI0808503B1/pt
Publication of BRPI0808503B8 publication Critical patent/BRPI0808503B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)

Abstract

a presente invenção refere-se a novos derivados de benzotiofeno substituídos por 2-heteroarila, precursores destes e usos terapêuticos de tais compostos tendo a fórmula estrutural (1a) abaixo: e aos seus sais farmaceuticamente aceitáveis , composições e métodos de usos. além disso, a invenção refere-se a novos derivados de benzotiofeno e benzofurano substituídos por 2-heteroarila que são adequados para formação de imagem de depósitos de amilóide em pacientes vivos, suas composições , métodos de uso e processos para fabricar tais compostos. mais especificamente , a presente invenção refere-se a um método de formação de imagem de depósitos de amilóide no cérebro in vivo para permitir o diagnóstico anterior á morte do mal de alzheimer bem como a medição da eficácia clinica de agentes terapêuticos para o mal de alzheimer.
BRPI0808503A 2007-03-06 2008-03-05 composto, uso de um composto, e, composição farmacêutica BRPI0808503B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89314907P 2007-03-06 2007-03-06
US60/893149 2007-03-06
US60/893,149 2007-03-06
PCT/SE2008/050243 WO2008108730A1 (en) 2007-03-06 2008-03-05 Novel 2-heteroaryl substituted benzothiophenes and benzofuranes 709

Publications (3)

Publication Number Publication Date
BRPI0808503A2 BRPI0808503A2 (pt) 2014-08-19
BRPI0808503B1 BRPI0808503B1 (pt) 2020-09-29
BRPI0808503B8 true BRPI0808503B8 (pt) 2021-05-25

Family

ID=39738510

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808503A BRPI0808503B8 (pt) 2007-03-06 2008-03-05 composto, uso de um composto, e, composição farmacêutica

Country Status (23)

Country Link
US (1) US7772256B2 (pt)
EP (1) EP2132201B1 (pt)
JP (1) JP5631009B2 (pt)
KR (1) KR101530392B1 (pt)
CN (2) CN101675042B (pt)
AR (1) AR065599A1 (pt)
AU (1) AU2008221668B2 (pt)
BR (1) BRPI0808503B8 (pt)
CA (1) CA2680157C (pt)
CL (1) CL2008000645A1 (pt)
CO (1) CO6220965A2 (pt)
EC (1) ECSP099641A (pt)
ES (1) ES2615381T3 (pt)
IL (1) IL200524A0 (pt)
MX (1) MX2009009469A (pt)
MY (1) MY147347A (pt)
NZ (1) NZ579157A (pt)
PE (1) PE20090164A1 (pt)
SA (1) SA08290097B1 (pt)
TW (1) TW200901998A (pt)
UA (1) UA98481C2 (pt)
UY (1) UY30951A1 (pt)
WO (1) WO2008108730A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール
JP5630867B2 (ja) 2008-08-05 2014-11-26 第一三共株式会社 イミダゾピリジン−２−オン誘導体
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
EP2388255A1 (en) 2010-05-11 2011-11-23 Ikerchem, S.L. Polysubstituted benzofurans and medicinal applications thereof
WO2012017891A1 (ja) * 2010-08-06 2012-02-09 国立大学法人京都大学 ピリジルベンゾフラン誘導体
KR20200118005A (ko) * 2018-02-05 2020-10-14 위니베르시떼 드 스트라스부르 통증 치료용 화합물 및 조성물
WO2021023813A1 (en) * 2019-08-06 2021-02-11 Domain Therapeutics 5-heteroaryl-pyridin-2-amine confounds as neuropeptide ff receptor antagonists

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU523040B2 (en) 1978-05-15 1982-07-08 Kanebo Limited Calcium -antagonistic composition
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
CA2034309C (en) 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
JPH09507071A (ja) * 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
US5518713A (en) 1995-02-13 1996-05-21 3V Inc. Benzoxazole derivatives, the use thereof as sunscreens and cosmetic compositions containing them
JPH11116476A (ja) 1997-10-16 1999-04-27 Sankyo Co Ltd 縮合複素環化合物
ES2536449T3 (es) 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
WO2002055496A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
JP4307001B2 (ja) * 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US6696039B2 (en) 2001-04-23 2004-02-24 Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
GB0130305D0 (en) * 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
WO2003106439A1 (ja) 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
TW200401194A (en) 2002-07-11 2004-01-16 Advanced Micro Devices Inc Method and apparatus for determining a processor state without interrupting processor operation
ATE425753T1 (de) * 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc Biaryl-verbindungen mit antiinfektiver wirkung
JP2004250411A (ja) 2003-02-21 2004-09-09 Bf Kenkyusho:Kk アミロイドβ蓄積性疾患の診断プローブおよび治療用化合物
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US20060276433A1 (en) 2003-03-31 2006-12-07 Keiichi Kawagoe Hydrazone derivative
AU2004238508B2 (en) 2003-05-13 2009-11-19 F. Hoffmann-La Roche Ag Imidazo-benzothiazoles
WO2005003101A2 (en) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Pyrazine and pyridine derivatives as rho kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006125324A1 (en) 2005-05-27 2006-11-30 Queen's University At Kingston Treatment of protein folding disorders
CA2614116A1 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Novel medicaments
WO2007033080A2 (en) 2005-09-12 2007-03-22 Emory University Alzheimer's disease imaging agents
EP1937260A2 (en) 2005-09-16 2008-07-02 University of Pittsburgh In-vivo and in-vitro method for detecting amyloid deposits having at least one amyloidogenic protein
SI1945622T1 (sl) 2005-10-11 2012-05-31 Univ Pittsburgh Izotopično markirane spojine benzfurana kot označevalne snovi za amiloidogenske proteine
JP4738419B2 (ja) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
KR20090101469A (ko) 2007-01-22 2009-09-28 아스트라제네카 아베 신규 헤테로아릴 치환된 이미다조〔１，２­ａ〕피리딘 유도체
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes

Also Published As

Publication number Publication date
AU2008221668B2 (en) 2011-03-31
IL200524A0 (en) 2010-04-29
EP2132201B1 (en) 2016-11-16
WO2008108730A1 (en) 2008-09-12
EP2132201A4 (en) 2011-05-25
CN102617556A (zh) 2012-08-01
PE20090164A1 (es) 2009-05-03
ES2615381T3 (es) 2017-06-06
JP2010520276A (ja) 2010-06-10
CN101675042A (zh) 2010-03-17
JP5631009B2 (ja) 2014-11-26
CN101675042B (zh) 2012-06-13
CA2680157A1 (en) 2008-09-12
AR065599A1 (es) 2009-06-17
AU2008221668A1 (en) 2008-09-12
KR20090117892A (ko) 2009-11-13
UA98481C2 (en) 2012-05-25
MX2009009469A (es) 2009-09-15
BRPI0808503A2 (pt) 2014-08-19
MY147347A (en) 2012-11-30
US7772256B2 (en) 2010-08-10
EP2132201A1 (en) 2009-12-16
KR101530392B1 (ko) 2015-06-22
CO6220965A2 (es) 2010-11-19
UY30951A1 (es) 2008-10-31
US20080221149A1 (en) 2008-09-11
ECSP099641A (es) 2009-10-30
SA08290097B1 (ar) 2011-10-29
CA2680157C (en) 2016-04-12
RU2009133257A (ru) 2011-04-20
TW200901998A (en) 2009-01-16
BRPI0808503B1 (pt) 2020-09-29
NZ579157A (en) 2012-04-27
CL2008000645A1 (es) 2008-10-24

Similar Documents

Publication Publication Date Title
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
ECSP088645A (es) Nuevos benzotiazoles sustituidos con heteroaril
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
ES2218531T3 (es) Arilalquilaminas activas sobre los receptores del calcio.
WO2009155017A3 (en) Novel substituted azabenzoxazoles
ES2584653T3 (es) Sonda para la obtención de imágenes de Tau
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
DOP2006000084A (es) Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
NI201100100A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1.
ECSP12011857A (es) Compuestos de dióxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
NO20064412L (no) Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav
EA200801529A1 (ru) Кристаллические формы 1-бензоил-4-[2-[4-метокси-7-(3-метил-1h-1,2,4-1-ил)-1-[(фосфонокси)метил]-1h-пирроло[2,3-c]пиридин-3-ил]-1,2-диоксоэтил]пиперазина
AR114029A2 (es) Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos
BRPI0606321A2 (pt) tetraidropiridinas 3,4,(5)-substituìdas
CN107353316A (zh) 用于治疗神经变性疾病的尿苷二磷酸衍生物、组合物和方法
TW201444860A (zh) 脲嘧啶核苷衍生物、組合物及使用方法
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
WO2010051196A8 (en) Novel substituted azabenzoxazoles
ECSP099082A (es) Beta-agonistas enantioméricamente puros, procedimientos para su preparación y su uso como medicamentos
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
BR112021012834A2 (pt) Derivados de pirimidina para a prevenção e tratamento de infecções bacterianas gram-negativas
WO2024186584A3 (en) Alpha-synuclein binders and methods of use

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF